Amarin is a pharmaceutical company leading a new paradigm in cardiovascular disease management. Community Guidelines: http://bit.ly/2L7xEW6
Intended for U.S residents only.
Intended for U.S residents only.
Location: United States, New Jersey, Bridgewater Township
Employees: 501-1000
Phone: +1 908-719-1315
Founded date: 1991
Investors 7
Mentions in press and media 9
| Date | Title | Description |
| 19.09.2024 | Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative dise... |
| 10.09.2024 | Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer | Industry veteran Daoud brings more than 25 years' experience in business development and corporate finance and strategy at multiple leading biopharmaceutical organizations WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Affinia Therapeutics ... |
| 02.07.2021 | Amarin : Reports Second Quarter 2014 Financial Results and Provides Update on Operations | Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations August 7, 2014 at 4:01 PM EDT Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations126.4 KB BEDMINSTER, NJ and DUBLIN, I... |
| 18.02.2021 | Head of NYU Langone's Naik Lab, Shruti Naik, to be Session Leader at Upcoming Vanguard Network Forum | NEW YORK (PRWEB) February 18, 2021 The Vanguard Network, which uniquely supports C-suite members in building their leadership capabilities, today announced that Shruti Naik, head of the Naik Lab at NYU Langone (https://naiklab.com/) will be... |
| 31.03.2020 | Amarin’s shares sink as federal judge invalidates patent on cardiovascular drug | Shares of Amarin fell 67% following the ruling on the Nasdaq and were down more than 68% when markets opened Tuesday. Shares of Dr. Reddy’s and Hikma were up more than 4% on the National Stock Exchange of India and 2.7% on the London Stock ... |
| 09.08.2019 | Regulatory, manufacturing setbacks hit several biopharma companies | First, on Tuesday, the Food and Drug Administration took the unusual step of publicly criticizing Swiss drugmaker Novartis for the alleged inclusion of some manipulated animal data in its regulatory approval application for the gene therapy... |
| 05.12.2007 | Life sciences briefing: Wednesday, Dec. 5, 2007 | Featured companies: AxoGen, Cognition Therapeutics, Ester Neurosciences, Gene Security Network, HealthTalk, MPM Capital, Revolution Health, SparkPeople UPDATING: Expanded items on AxoGen, Ester and Cognition. Posted full items on MPM (link)... |
| - | Amarin’s shares sink as federal judge invalidates patent on cardiovascular drug | A federal court in Nevada struck down the patent protection on a drug used to lower the risk of heart attacks, sending the manufacturer’s shares diving. Las Vegas District Judge Miranda Du ruled Monday in favor of two generic companies that... |
| - | Regulatory, manufacturing setbacks hit several biopharma companies | Many people remember the 1972 children’s book “Alexander and the Terrible, Horrible, No Good, Very Bad Day,” a comical story of an eponymous boy whose day goes wrong at almost every turn. While it hasn’t been all bad news, the book’s overal... |